000			05069cam a22004818i 4500
001			22419368
003			BJBSDDR
005			20240507114916.0
006			m |o d |
007			ta
008			220207s2022 mau 001 0 eng
010			_a 2022001932
020			_a9781647823207 _q(epub)
020			_z9781647823191 _q(hardcover)
040			_aDLC _bspa _cDLC _erda
041			_aeng
042			_apcc
050	1	4	_aHD 9668.5 _bL829m 2022
082	0	0	_a338.4/76153 _223/eng/20220210
100			_aLotus,Peter _q(Peter D.), _eauthor. _935513
245	1	4	_aThe messenger : _bModerna, the vaccine, and the business gamble that changed the world / _cPeter Loftus.
263			_a2207
264		1	_aBoston, Massachusetts : _bHarvard Business Review Press, _c[2022]
300			_a307 page. _c24 cm
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
500			_aIncludes index.
505	0		_aPrologue. Disease X -- Changing the Fate -- If This Is True -- Kendall Square -- Feeding the Beast -- Broke Offer -- No Boundaries -- mRNA- -- More Money -- Warp Speed -- Hold On, Help Is On the Way -- Politics Protocols and Patents -- The Power of Science -- Evidence -- Happy Tears -- Delta -- Just the Beginning.
520			_a"At the start of 2020, Moderna was a waning biotech unicorn, still years away from delivering its first product despite a decade of development of a potentially breakthrough innovation: using RNA to combat disease. Investors were getting antsy or, worse, skeptical. Then the coronavirus pandemic hit, and Moderna became a central player in a global drama-a David to pharma's Goliaths-turning its technology toward breaking the global grip of the terrible disease. By year's end, as the outbreak was at its worst, Moderna delivered one of the world's first Covid-19 vaccines, with a stunningly high rate of protection. The achievement not only offered the world a way out of a crippling pandemic but also validated Moderna's gene-based technology, transforming the company into a global industry power, swelling its market value on its prospects for new drugs and vaccines for years to come. Biotech, and the venture capital community that fuels it, will never be the same. Wall Street Journal reporter Peter Loftus, part of a Pulitzer Prize-finalist reporting team and 25-year veteran reporter in the pharmaceutical and biotech industries, brings the inside story of how Moderna went all in on a single revolutionary idea; of quiet research with unknown consequence; of the evolution of a cutting-edge American innovation, industry, and economy-decades in the making-that led to one of the great gambles in business history"-- _cProvided by publisher.
588			_aDescription based on print version record and CIP data provided by publisher; resource not viewed.
610	2	0	_aModerna (Firm) _xHistory.
650		0	_aVaccines industry _xHistory.
650		4	_aIndustria farmacéutica _xVacunas _xHistoria _932400
650		0	_aPharmaceutical biotechnology industry _xEconomic aspects _xHistory.
650		4	_aIndustria farmacéutica _xAspectos económicos _xHistoria _932400
650		0	_aMessenger RNA.
650		0	_aARN mensajero _935745
776	0	8	_iPrint version: _aLoftus, Peter _tMessenger _dBoston, Massachusetts : Harvard Business Review Press, [2022] _z9781647823191 _w(DLC) 2022001931
906			_a7 _bcbc _corignew _d1 _eecip _f20 _gy-gencatlg
942			_2lcc _cBK _n0
999			_c121136 _d121136